Raffit Hassan

Title: Innovations of Inventor Raffit Hassan

Introduction

Raffit Hassan is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies targeting mesothelin, a protein associated with various cancers. With a total of 2 patents, his work has the potential to impact cancer treatment and diagnostics.

Latest Patents

Hassan's latest patents focus on mesothelin domain-specific monoclonal antibodies and their applications. The patents describe the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin monoclonal antibodies (mAbs) that bind to specific regions of mesothelin. Notably, the identified mAbs, including YP187, YP223, YP218, and YP3, exhibit binding to either Region II (391-486) or Region III (487-581) of mesothelin with subnanomolar affinity. Importantly, these antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or the mesothelin-specific antibody MORAb-009. Additionally, a high-affinity rabbit mAb, YP158, has been disclosed, which binds to Region I of mesothelin, demonstrating high affinity and specificity for native mesothelin protein in cancer cells and tissues.

Career Highlights

Raffit Hassan is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to focus on innovative research that bridges the gap between laboratory findings and clinical applications.

Collaborations

Hassan has collaborated with esteemed colleagues, including Mitchell Ho and Ira H Pastan. These collaborations have further enhanced the research and development of effective therapeutic strategies targeting mesothelin.

Conclusion

Raffit Hassan's contributions to the field of monoclonal antibody research are noteworthy, particularly in the context of cancer treatment. His innovative work continues to pave the way for advancements in targeted therapies, showcasing the importance of research in improving patient outcomes.